Summary:
A randomized, parallel-group, placebo-controlled, clinical endpoint bioequivalence study of feneric fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder compared with advair diskus 100/50 in subjects with asthma.
Qualified Participants Must:
Have Asthma
Be over 12 years of age
Use at least one asthma inhaler
Not have cancer history in past 5 years
Qualified Participants May Receive:
Compensation for clinic visit and travel